trial · primary record
Selinexor
Multiple Myeloma, Refractory
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 127 |
| Primary completion | 2028-01 |
| Primary endpoint | Overall Response Rate (ORR) |
| Registry ID | NCT04414475 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-29T14:32:08.966Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04414475
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.